REPLIMUNE GROUP INC (REPL) Stock Price & Overview
NASDAQ:REPL • US76029N1063
Current stock price
The current stock price of REPL is 6.98 USD. Today REPL is up by 1.31%. In the past month the price decreased by -19.21%. In the past year, price decreased by -35.49%.
REPL Key Statistics
- Market Cap
- 576.339M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.44
- Dividend Yield
- N/A
REPL Stock Performance
REPL Stock Chart
REPL Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to REPL. When comparing the yearly performance of all stocks, REPL is a bad performer in the overall market: 88.93% of all stocks are doing better.
REPL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to REPL. Both the profitability and financial health of REPL have multiple concerns.
REPL Earnings
REPL Forecast & Estimates
14 analysts have analysed REPL and the average price target is 13.11 USD. This implies a price increase of 87.88% is expected in the next year compared to the current price of 6.98.
For the next year, analysts expect an EPS growth of -13.46% and a revenue growth -100% for REPL
REPL Groups
Sector & Classification
REPL Financial Highlights
Over the last trailing twelve months REPL reported a non-GAAP Earnings per Share(EPS) of -3.44. The EPS decreased by -12.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -94.38% | ||
| ROE | -149.55% | ||
| Debt/Equity | 0.33 |
REPL Ownership
REPL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.82 | 364.65B | ||
| AMGN | AMGEN INC | 15.24 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.68 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.84 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.29 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.55 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About REPL
Company Profile
Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 479 full-time employees. The company went IPO on 2018-07-20. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Company Info
IPO: 2018-07-20
REPLIMUNE GROUP INC
500 Unicorn Park Dr
Woburn MASSACHUSETTS 01801 US
CEO: Philip Astley-Sparke
Employees: 479
Phone: 17812229600
REPLIMUNE GROUP INC / REPL FAQ
What does REPL do?
Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 479 full-time employees. The company went IPO on 2018-07-20. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
What is the stock price of REPLIMUNE GROUP INC today?
The current stock price of REPL is 6.98 USD. The price increased by 1.31% in the last trading session.
Does REPL stock pay dividends?
REPL does not pay a dividend.
How is the ChartMill rating for REPLIMUNE GROUP INC?
REPL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is REPLIMUNE GROUP INC (REPL) stock traded?
REPL stock is listed on the Nasdaq exchange.
Can you provide the market cap for REPLIMUNE GROUP INC?
REPLIMUNE GROUP INC (REPL) has a market capitalization of 576.34M USD. This makes REPL a Small Cap stock.
Can you provide the upcoming earnings date for REPLIMUNE GROUP INC?
REPLIMUNE GROUP INC (REPL) will report earnings on 2026-05-20, after the market close.